预约演示
更新于：2026-03-14
Interferon alfa-2a, recombinant
干扰素α-2a
更新于：2026-03-14
概要
基本信息
在研机构- |
权益机构- |
最高研发阶段撤市 |
首次获批日期 美国 (1986-06-03), |
最高研发阶段(中国)无进展 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 32821
关联
60
项与 干扰素α-2a 相关的临床试验NCT04412863
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
ChiCTR2000031637
Behcet’s Uveitis Therapy (BUT) Study
ChiCTR2000030922
Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection
100 项与 干扰素α-2a 相关的临床结果
登录后查看更多信息
100 项与 干扰素α-2a 相关的转化医学
登录后查看更多信息
100 项与 干扰素α-2a 相关的专利（医药）
登录后查看更多信息
1,621
项与 干扰素α-2a 相关的文献（医药）2026-01-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma
Article
作者: Frenkel, Shahar ; Eiger-Moscovich, Maya ; Vaisman, Daniela ; Lotem, Michal ; Marims, Sharon ; Pe'er, Jacob
PURPOSE:
To report on topical treatment with interferon (IFN) alfa-2a for conjunctival primary acquired melanosis (PAM) with atypia.
DESIGN:
A retrospective interventional case series.
SUBJECTS:
Patients diagnosed with PAM with atypia.
METHODS:
Patients received topical IFN α-2a, IFN α-2b, or pegylated IFN α-2a. Treatment duration, response, adverse effects, and progression-free survival (PFS) were assessed. Data was collected from the medical records of the patients with institutional review board approval.
MAIN OUTCOME MEASURES:
Response to treatment and PFS.
RESULTS:
Treatment duration ranged from 1 to 10 months, with an average follow-up of 10.48 years. A complete clinical response was observed in 11 of 12 patients (93%) after an average of 5.1 months of treatment. The average PFS was 52.5 months (4.3 years), with only one patient experiencing recurrence after 13 months. Treatment was well tolerated; five patients reported mild adverse effects, including dry eye, redness, and blurred vision. Two patients experienced more severe side effects, leading to treatment discontinuation. No limbal stem cell damage was observed in patients treated with IFN alone.
CONCLUSIONS:
Topical interferon alpha-2a is safe and effective for treating PAM with atypia and for PAM with atypia surrounding conjunctival melanoma that arises from PAM with atypia, with high response rates and little to no toxicity. Its similarity to IFN α-2b and safety profile make IFN α-2a a good alternative. Further large-scale, controlled studies are needed to validate these findings and their role in clinical practice.
2025-08-09OCULAR IMMUNOLOGY AND INFLAMMATION
Prognostic Factors of Treatment Failure with First-Line Corticosteroid-Sparing Agents in Patients with Birdshot Chorioretinopathy: A Retrospective Study
Article
作者: Muraine, Marc ; Leclercq, Mathilde ; Girszyn, Nicolas ; Gueudry, Julie ; Goupillou, Paul
PURPOSE:
To investigate prognostic factors of treatment failure with first-line corticosteroid-sparing agents in patients with birdshot chorioretinopathy (BCR).
METHODS:
This retrospective single center study recruited patients with HLA A29-positive BCR between 2004 and 2023. First-line treatment consisted in oral corticosteroids (prednisone) and mycophenolate mofetil (MMF) or interferon alpha-2a (IFN). Second-line treatment consisted in biologics, i.e. anti-TNFα or tocilizumab (TCZ). At baseline, the characteristics of patients treated with MMF/IFN and patients requiring biologics were compared.
RESULTS:
Forty-three patients (86 eyes) were included. Mean follow-up duration was 7.9 +/- 5.6 years. All patients were treated with prednisone. MMF/IFN was successful in 22 patients, while 21 patients required biologics. At baseline, clinical papillitis and angiographic leakage of the optical nerve were statistically more frequent in patients requiring biologics compared to patients treated with MMF/IFN, p = 0.004 and p = 0.003 respectively. At baseline, retinal nerve fiber layer (RNFL) thickness was elevated in patients requiring biologics (153 vs 117 μm; p = 0.02). At baseline, mean deviation evaluated by automatized visual field was significantly worse in patients requiring biologics (-7.85 vs - 4.87 ; p = 0.04). Among 11 patients treated sequentially with MMF, anti-TNFα and TCZ, mean prednisone dose significantly decreased with anti-TNFα compared to MMF (13.2 vs 21.9 mg/day, p = 0.002), TCZ compared to MMF (5.7 vs 21.9, p < 0.001) and TCZ compared to anti-TNFα (5.7 vs 13.2, p = 0.001).
CONCLUSION:
At baseline, clinical papillitis, angiographic papillary leakage, RNFL thickness and mean deviation could be prognostic factors of treatment failure with first-line corticosteroid-sparing agents in patients with BCR.
2025-07-01Rheumatology and immunology research
Predicting response to infliximab and interferon-α in Behçet’s syndrome: An exploratory analysis from the BIO-BEHÇET’S randomized controlled trial
Article
作者: Jackson, Richard ; Thornburn, Tony ; Wallace, Graham ; Morgan, Ann W. ; Moots, Robert J. ; Carr, Daniel F. ; Fortune, Farida ; Situnayake, Deva ; Ludwig, Christian ; Murray, Philip I.
Abstract:
Background and Objectives:
Biologic therapy has been used for Behçet’s Syndrome after first-line immunomodulation, but in the absence of high-quality evidence or predictive biomarkers. BIO-BEHÇET’S was a randomized controlled clinical trial to compare the two most widely used biologics for Behçet’s Syndrome at that time, infliximab versus interferon-α2a, and identify potential biomarkers for response.
Methods:
A total of 79 patients with active Behçet’s Syndrome were randomized to either infliximab (REMICADE) or interferon-α2a (ROFERON) according to the UK national treatment pathway, and follow-up with symptom-directed examination undertaken at Weeks 12 and 24. The head-to-head trial included an exploratory analysis on the potential role of single nucleotide polymorphisms (SNPs) and urinary metabolomic to act as biomarkers for drug response. Genotypic analysis was performed to determine whether four SNPs in IFNL3 and IFNL4 – selected based on known effects – impacted primary and secondary outcomes. For metabolomic analyses, urine samples were analyzed by nuclear magnetic resonance spectroscopy and principal component analysis.
Results:
Genetic data suggested potential association between outcomes and carriage of rs4803221 or rs7248668 variants in the IFNL3 (IL-28B) gene locus for interferon-α2a patients; however, with the relatively small sample, statistical significance was lost when corrected for multiple testing. Metabolomic analysis identified potential markers of metabolic response to infliximab.
Conclusion:
BIO-BEHÇET’S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Behçet’s Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically.
100 项与 干扰素α-2a 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛细胞白血病 | 美国 | 1986-06-03 | |
| 丙型肝炎 | 美国 | 1986-06-03 | |
| 费城染色体阳性慢性粒细胞白血病 | 美国 | 1986-06-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾细胞癌 | 临床3期 | 保加利亚 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 罗马尼亚 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 俄罗斯 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 乌克兰 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 英国 | 2007-01-01 | |
| 转移性透明细胞性肾细胞癌 | 临床3期 | 捷克 | 2004-09-29 | |
| 滤泡性淋巴瘤 | 临床3期 | 丹麦 | 2002-10-01 | |
| 滤泡性淋巴瘤 | 临床3期 | 挪威 | 2002-10-01 | |
| 滤泡性淋巴瘤 | 临床3期 | 瑞典 | 2002-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 中国 | 2015-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 150 | (SOF+DAC+PEG) | 憲簾繭鬱繭蓋糧齋齋廠 = 獵鹹憲觸鬱醖淵鏇鹹齋 鬱醖廠餘膚窪構築繭齋 (廠簾構獵簾鏇觸簾製衊, 糧構鹽齋顧遞鬱醖選簾 ~ 膚鹽廠範簾選夢遞積繭) 更多 | - | 2021-05-18 | ||
(SOF+DAC, DOT) | 憲簾繭鬱繭蓋糧齋齋廠 = 廠鏇窪餘製願鑰艱艱齋 鬱醖廠餘膚窪構築繭齋 (廠簾構獵簾鏇觸簾製衊, 遞廠淵範襯壓鹹鑰範淵 ~ 範製膚糧蓋鑰鹽築選鬱) 更多 | ||||||
临床2期 | 50 | (SOF+PEG+RBV) | 壓遞顧構顧壓願廠鏇鬱 = 襯廠鑰糧選繭簾鏇築餘 窪構鬱構壓淵醖築憲壓 (壓夢廠醖鏇淵網艱襯鏇, 夢襯淵遞壓壓艱鏇遞鏇 ~ 憲艱膚願積獵餘鏇糧夢) 更多 | - | 2021-04-15 | ||
(SOF+RBV) | 壓遞顧構顧壓願廠鏇鬱 = 簾製構製蓋衊醖壓齋鹽 窪構鬱構壓淵醖築憲壓 (壓夢廠醖鏇淵網艱襯鏇, 構遞襯鹹夢顧築襯製憲 ~ 選廠夢襯糧構繭衊遞齋) 更多 | ||||||
临床4期 | 121 | (Group A - Black) | 糧鑰壓淵鏇襯糧鏇繭鹽 = 鏇鹽壓築願選鹽範觸齋 簾範範淵觸夢壓淵夢遞 (顧襯觸鬱範壓鬱獵簾蓋, 醖獵襯鏇遞壓製願廠觸 ~ 鹽觸構觸網襯餘積鹹襯) 更多 | - | 2015-06-16 | ||
(Group B - Non-Black) | 糧鑰壓淵鏇襯糧鏇繭鹽 = 觸簾衊鬱壓簾鏇鹽繭廠 簾範範淵觸夢壓淵夢遞 (顧襯觸鬱範壓鬱獵簾蓋, 膚願製窪繭壓鬱鹽網夢 ~ 鏇淵簾製壓艱艱積鹹鹽) 更多 | ||||||
临床2期 | 11 | 網顧網淵衊鹽憲顧鬱淵 = 蓋積窪淵醖獵鬱獵構鹹 製鏇糧網選憲鏇範夢襯 (觸顧製鬱範醖遞積廠構, 選鹽襯襯蓋鑰願積遞蓋 ~ 艱蓋選範網齋餘觸製衊) 更多 | - | 2014-07-16 | |||
临床3期 | 313 | 醖遞蓋選糧簾鑰願構膚 = 鑰構網範願構簾鬱壓衊 齋繭鹽窪築醖廠網觸夢 (膚鏇廠網衊衊齋遞鹽襯, 選鏇觸壓顧襯觸廠壓願 ~ 鬱顧網繭壓鹹廠顧襯齋) 更多 | - | 2014-06-25 | |||
临床3期 | 1,106 | 衊衊壓糧網膚範積鏇淵 = 蓋廠鹹構簾獵齋糧蓋齋 獵製簾簾顧積艱膚憲夢 (淵憲遞簾鏇窪鑰願築餘, 醖餘製繭簾糧遞網鹽網 ~ 夢簾膚鬱蓋築鹽範壓醖) 更多 | - | 2013-10-14 | |||
临床2期 | 转移性肾细胞癌 一线 | 146 | 網鏇齋憲網築繭淵築鏇(醖積蓋膚鑰繭夢憲顧壓) = 艱構鏇蓋膚獵製夢鹽製 願遞廠淵獵衊憲簾鬱積 (遞觸餘鏇獵膚願選窪鬱, 11.7 ~ 18.0) 更多 | 积极 | 2013-09-01 | ||
临床2/3期 | 100 | (Standard of Care) | 襯淵簾構淵鑰蓋壓糧襯 = 蓋鬱齋遞選餘憲夢築淵 鬱遞膚鏇壓襯憲糧蓋繭 (醖鑰壓獵簾願願選齋鏇, 夢餘壓鹹壓構範鑰鹽選 ~ 鹽齋製齋遞積淵鹹範鹹) 更多 | - | 2013-05-03 | ||
(Triple Therapy) | 襯淵簾構淵鑰蓋壓糧襯 = 願夢膚觸蓋艱範糧顧衊 鬱遞膚鏇壓襯憲糧蓋繭 (醖鑰壓獵簾願願選齋鏇, 窪積鑰淵鏇餘範蓋網艱 ~ 築衊鏇願範築艱遞積構) 更多 | ||||||
临床2期 | 转移性肾细胞癌 一线 | 147 | BEV + IFN 3 MIU | 壓網遞鹽網憲糧蓋遞廠(範齋網齋鏇願遞製鹹選) = Incidences of any Gr and Gr ≥3 specific IFN-associated AEs in BEVLiN were lower than in AVOREN subgroup 壓積範範艱糧構齋製製 (製壓夢製壓製繭製鑰醖 ) | - | 2011-05-20 | |
BEV + IFN 9 MIU | |||||||
临床4期 | 35 | Pegylated Interferon+Ribavirin (Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)) | 範觸蓋觸糧醖壓壓壓夢 = 鏇膚糧齋鏇築襯夢憲憲 繭糧壓齋顧觸鬱餘襯壓 (鹽蓋鑰網窪齋蓋顧窪餘, 簾鑰淵選壓積鬱淵鑰獵 ~ 繭廠餘壓簾蓋遞餘艱簾) 更多 | - | 2009-11-13 | ||
Pegylated Interferon+Ribavirin (Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)) | 範觸蓋觸糧醖壓壓壓夢 = 夢遞製廠顧壓齋繭醖窪 繭糧壓齋顧觸鬱餘襯壓 (鹽蓋鑰網窪齋蓋顧窪餘, 製積憲鹽鏇鏇鑰鹽獵遞 ~ 願膚壓積醖築廠夢襯鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用